Accessibility
Contact
Creating sophisticated gene
therapy solutions to treat
complex eye diseases
We are on a mission to treat common causes of sight-loss with advanced gene therapy
Normal Vision
Discovering new therapies
Treating Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is the leading cause of irreversible vision loss in individuals over 60 years of age.
The condition starts as Dry AMD and as central vision gradually deteriorates it becomes increasingly difficult to read and recognize faces. Wet AMD develops in 10-15% of cases and if left untreated, can lead to very sudden and significant vision loss. The global number of people with AMD is projected to be 288M by 2040
Learn more about AMD
Who we are
Ikarovec is a leader in ophthalmology innovation, with sophisticated, field-changing technology for the long-term relief of prevalent eye diseases
Ikarovec is advancing a pipeline of next generation gene therapies to treat major chronic eye diseases. For patients, Ikarovec’s products will mean continuous life-long sight preservation, freeing them from current burdensome, repetitive treatments with one single injection.
Learn more about us
Building novel bi-functional gene therapies to treat sight loss
Ikarovec’s innovative bi-functional gene therapy delivers genetic instructions for two clinically relevant proteins that each target different aspects of the disease, addressing multiple pathways involved in its progression. This approach offers a superior therapeutic advantage over single-target treatments for the growing population affected by ophthalmic diseases.
Learn more about our Technology
Partner with Ikarovec
Join us in transforming ophthalmic care—contact us to explore opportunities to collaborate.
Reach out